Ann: Application for quotation of securities - SPL, page-8

So before the AGM the questions are below and at AGM obviously the harder follow up non answers. Now some here know most of the below answers but it might be a wake up call for other shareholders to drill down and actually discover why Viraleze isn't in shops all over Europe and same in rest or world even though seemingly KPI's were achieved?

You could always ask SPL and ASX
Exactly what was the key hurdles/ barriers that the TGA set that SPL was unable to provide in having Viaraleze approved as a medical device.
What date was SPL first notifies of these barriers / hurdles and what date was SPL aware it would not have data to meet them? What date did SPL receive notification from TGA it had not met required hurdles / barriers?

Then
Italian distribution - Is it still happening
Are Admenta Mckesson Lloydsfarmacia still the holder to Europe distribution and if so why no distribution outside of Italy? What Italian rules allowed retail in that country and is that different to rest of Europe.?
When was the last specific EU production run and an its expiry date?
Is it still available in retail stores? on shelf
Is there any minimum performance and volume or $ in contract? If not why not?
Last order from them?
Does UK trial failure to meet endpoint affect sale in Italy / Europe? Is there a deadline in regards to this?
Does Italy / Europe require new labeling , boxes or insets?
Does UK trial change marketing or Advertising claims that can be made in any jurisdiction ?


Basically same questions regarding UK distribution . Adding in future will SPL take control or modifty agreements so "dumping" of discounted short dated stock doesn't end up in secondary marketplace?
Same questions regarding Vietnamese distribution

New Zealand - knowing the close relationship with TGA is purchase in New Zealand likely to be affected by results of Failure to meet endpoint of UK trial

Same questions regarding other markets they have claimed distribution?

Exactly in what countries in the world is Viraleze available directly via retail in a shop? Via website ?
Will you announce any changed to availability and distribution in any country?

I don't know what the full story is but IMO in business to sign distribution agreements that don't have min performance , value and volume requirements means non performers are hard to get rid of when they decide to not sell product or to not put energy into distribution. We never get to see details of SPL agreements so is guesswork based on results we see in market as little feedback or mention in SPL reports. These IMO would be poor deals to enter as hard to get out off and reallocate to another active distributor or impose penalty. It delays the widespread use of product and its market recognition and affects sales in all regions IMO